摘要
目的观察拜阿司匹林联合阿托伐他汀治疗缺血性脑血管病的效果和安全性。方法选择我院2013年1月至2014年6月颈部彩超证实存在颈部动脉斑块的缺血性脑血管病患者86例,采用数字表随机法分为两组,对照组43例在基础治疗的同时给予拜阿司匹林口服,观察组43例在对照组治疗的基础上联合阿托伐他汀口服,比较治疗前、治疗12个月后两组患者的血清氧化低密度脂蛋白(Ox LDL)、超敏C反应蛋白(hs-CRP)与颈部动脉中膜厚度(IMT)的变化,记录用药过程中的不良反应。结果治疗12个月后观察组Ox LDL、hs-CRP、IMT均较治疗前明显降低(P<0.05),且Ox LDL、hs-CRP、IMT均低于对照组(P<0.05);两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论拜阿司匹林联合阿托伐他汀可降低缺血性脑血管病患者Ox LDL和hs-CRP水平,对动脉粥样硬化斑块的逆转具有积极的意义。
Objective To observe the efficacy and safety of atorvastatin combined with aspirin in treating ischemic cerebrovascular disease(ICVD). Methods Eighty-six patients confirmed as ischemic cerebrovascular disease with carotid artery plaque by color ultrasound from January 2013 to June 2014 were selected, which were divided into two groups according to random number table. The control group(43 cases) received aspirin based on basic therapy, and the observation group(43 cases) applied atorvastatin based on the control group. Serum oxidized low density lipoprotein(Ox LDL), high-sensitivity C-reactive protein(hs-CRP), and intima-media thickness(IMT) of carotid artery were compared between the two groups before treatment and after 12 months of treatment. The adverse reactions during treatment were recorded. Results After 12 months of treatment, the levels of Ox LDL, hs-CRP, IMT in the observation group were decreased significantly compared with those before treatment(P<0.05), and the levels of Ox LDL, hs-CRP, IMT were significantly lower than those in the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Atorvastatin combined with aspirin can reduce Ox LDL and HS-CRP levels in patients with ischemic cerebrovascular disease, which is of positive significance for the reversal of atherosclerotic plaque.
出处
《海南医学》
CAS
2016年第1期30-31,共2页
Hainan Medical Journal
关键词
拜阿司匹林
阿托伐他汀
缺血性脑血管病
氧化低密度脂蛋白
超敏C反应蛋白
颈部动脉中膜厚度
影响
Aspirin
Atorvastatin
Ischemic cerebrovascular disease
Oxidized low density lipoprotein(OxLDL)
High-sensitivity C-reactive protein(hs-CRP)
Intima-media thickness(IMT)
Effect
